Skye Bioscience amends 8-K to correct option repricing share count to 2,458,158

Skye Bioscience, Inc.

Amendment corrects a scrivener's error: total shares underlying Repriced Options is 2,458,158.
No other changes to the original April 3, 2026 8-K filing on compensatory arrangements.
CEO Punit Dhillon signed the amendment dated April 6, 2026.

item 5.02

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-023903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.